Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients

Journal of Medical Virology

Volumn 60, Issue 1, 2000, Pages 8-16

  Seta, Toshikatsu ^a   Yokosuka, Osamu ^a   Imazeki, Fumio ^a   Tagawa, Masami ^a   Saisho, Hiromitsu ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiviral agent; Direct sequencing; HBV DNA polymerase; PCR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; DNA POLYMERASE; LAMIVUDINE; METHIONINE; TYROSINE; VIRUS DNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; VIRUS MUTANT; VIRUS MUTATION;

ADULT; ALANINE TRANSAMINASE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPETENCE; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 0033992324     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200001)60:1<8::AID-JMV2>3.0.CO;2-U     Document Type: Article

References (34)

1. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Gennip AH, Berkhout B. 1996. Reduced replication of 3TC-resistant HIV-I variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15:4040-4049.
2. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349: 20-22.
3. Beasly RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. Lancet ii:1129-1133.
4. Benhamou Y, Dohin E, Lunei-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M. 1995. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345:396-397.
5. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. 1996. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Int Med 125:705-712.
6. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM. 1993. High-level resistance to (-) enatiomeric 2′,3′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicr Agents Chemotherapy 37:2231-2234.
7. Chen D-S. 1993. Natural history of chronic hepatitis B virus infection: new light on an old story : J Gastroenterol Hepatol 8:470-475.
8. Coates JA, Cammack N, Jenkinson HJ. 1992. The separated enantiomers of 2′deoxy-3′-thiacytidine (BCH189) both inhibit human immunodeficiency virus replication in vitro. Antimicr Agents Chemotherapy 36:202-205.
9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
10. Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499.
11. Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. 1992. Variations in codon 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Inv 89:332-338.
12. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2, 3-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′, 3′-dideoxy -3′-thiacytidine. Antimicr Agents Chemo 37:1390-1392.
13. Girones R, Miller RH. 1989. Mutation rate of the hepadnavirus genome. Virology 170:595-597.
14. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Shalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 26:1393-1395.
15. Keulen W, Back NKT, van Wijk A, Boucher CAB, Berkhout B. 1997. Initial appearance of the 184 He variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus typel reverse transciptase. J Virol 71:3346-3350.
16. Lai C-H, Ching C-K, Tung AK-M, Li F, Young J, Hill A, Wong BC-Y, Dent J, Wu P-C. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
17. Lau D, Mostouski H, Hoofnagle JH, Sallie R .1994. Nucleoside analogue toxicity and mitochondria. Hepatology 20:189A. [Abstract]
18. Ling R, Mutiner D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
19. Lok ASF, Wu P-C , Lai C-L , Johnson YNL, Elsie KYL, Loretta SKW, Oliver CKM, Ian JL, Clara PLN, Chung H-T. 1992. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102:2091-2097.
20. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and Famiciclovir administration are replication defective. Hepatology 27:628-633.
21. Okamoto H, Imai M, Kametani M, Nakamura N, Mayumi N. 1987. Genomic heterogeneity of hepatitis B virus in a 34-year-old woman who contracted the infection through materno-fetal transmission. Japan J Exp Med 57:231-236.
22. Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima EN, Yamamoto M, Gojobori T. 1989. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Nat Acad Sci USA 86:7059-7062.
23. Pluda JM. Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, Hirst HM, Vicary CA, Quinn JB, Yuen GJ, Wainberg MA, Rubin M, Yarchoan R. 1995. The phase I/II study of 2′, 3′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Inf Dis 171: 1438-1447.
24. Schalm SW, de Man RA, Heijtink RA, Niesters HGM. 1995. New nucleoside analogues for chronic hepatitis B. J Hepatol 22(Suppl 1):52-56.
25. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J, Boucher CAB. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Inf Dis 171:1411-1419.
26. Severini A, Liu X-Y, Wilson JS, Tyrell DLJ. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-2′, 3′-dideoxy-3β-thiacytidine. Antimicro Agents Chemo 39:1430-1435.
27. Soudeyns H, Yao X-J, Belleau B, Kraus J-L, Nguyen-Ba N, Spira B, Wainberg MA. 1991. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′,3′-deoxy-3′-thiacytidine (BCH189), a novel heterocyclic nucleoside analogue. Antimicro Agents Chemo 35:1386-1390.
28. Tipples GM, Ma MM, Fischer KP, Bain VG, Kneteman NK, Tyrrell LJ. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
29. Tisdale M, Kemp SD, Lader BA. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Nat Acad Sci USA 90:5653-5656.
30. Tyrell TLJ, Michell MC, De Man RA, Shalm SW, Main J, Thomas HC, Fevery J, Nevens F, Beranek P, Vicary C. 1993. Phase II trial of lamivudine for chronic hepatitis B. Hepatology [Abstract] 18: 112A.
31. Van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, MacDade H, Banner SA. 1995. Evalution of safety and efficiency of 3TC (lamivudine) in patients with asymptomatic or mildly asymptomatic human immunodeficiency virus infections: a phaseI/II study. J Inf Dis 171: 1166-1171.
32. Wong DK, Cheung AM, O'Rourke K, Nayler CD, Detsky AS, Heathcote J. 1993. Effects of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Int Med 119:312-313.
33. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, Merigan TC, Gregory PB. 1984. Survival in chronic hepatitis B : an analysis of 379 patients. Ann Int Med 101:613-616.
34. Zoulium F, Trepo C. 1994. Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. J Hepatol 21: 142-144.